US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NOVONESIS A S

60.19

-1.2300-2.00%

Volume:73.14K

Turnover:4.41M

Market Cap:27.97B

PE:37.30

High:60.71

Open:60.25

Low:59.75

Close:61.42

52wk High:75.99

52wk Low:53.95

Shares:464.62M

Float Shares:345.19M

Volume Ratio:0.80

T/O Rate:0.02%

Dividend:0.96

Dividend Rate:1.60%

EPS(TTM):1.61

EPS(LYR):1.62

ROE:5.19%

ROA:4.40%

PB:2.21

PE(LYR):37.18

Loading ...

Overview Company News Filings

Novonesis price target lowered to DKK 540 from DKK 560 at JPMorgan

Novonesis price target raised to DKK 560 from DKK 512 at JPMorgan

Novonesis price target lowered to DKK 560 from DKK 569 at Morgan Stanley

Press Release: Novonesis delivered 8% organic sales growth in the first nine months of 2025

Novonesis and Novo Nordisk Collaborate to Improve Metabolic Health

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVZMY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NVZMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVZMY\",,,,,undefined,":{"symbol":"NVZMY","market":"US","secType":"STK","nameCN":"NOVONESIS A S","latestPrice":60.19,"timestamp":1771880400000,"preClose":61.42,"halted":0,"volume":73143,"delay":15,"changeRate":-0.020026050146532137,"floatShares":345188430,"shares":464616092,"eps":1.613472,"marketStatus":"Closed","change":-1.23,"latestTime":"02-23 16:00:00 EST Delay","open":60.25,"high":60.71,"low":59.75,"amount":4414577.2581,"amplitude":0.01563,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.613472,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":5,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":61.42,"volumeRatio":0.795804},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVZMY\",,,,,undefined,":{"symbol":"NVZMY","floatShares":345188430,"roa":"4.40%","roe":"5.19%","lyrEps":1.61875,"volumeRatio":0.795804,"shares":464616092,"dividePrice":0.960734,"high":60.71,"amplitude":0.01563,"preClose":61.42,"low":59.75,"week52Low":53.95,"pbRate":"2.21","psRate":"5.73","week52High":75.99,"institutionHeld":0,"latestPrice":60.19,"eps":1.613472,"divideRate":0.015962,"volume":73143,"delay":15,"ttmEps":1.613472,"open":60.25,"prevYearClose":63.62,"prevWeekClose":61.42,"prevMonthClose":61.31,"prevQuarterClose":63.62,"fiveDayClose":63.51,"twentyDayClose":64.07,"sixtyDayClose":61.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVZMY\",params:#limit:5,,,undefined,":[{"date":"2025-09-02","symbol":"NVZMY","amount":0.350101,"announcedDate":"2025-08-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-02","defaultRemindTime":1756819800000,"name":"NOVONESIS A S","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-11","payableDate":"2025-09-02","currency":"USD","dateTimestamp":1756785600000,"payDate":"2025-09-11"},{"date":"2025-04-07","symbol":"NVZMY","amount":0.610633,"announcedDate":"2025-03-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-07","defaultRemindTime":1744032600000,"name":"NOVONESIS A S","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-23","payableDate":"2025-04-07","currency":"USD","dateTimestamp":1743998400000,"payDate":"2025-04-23"},{"market":"US","date":"2025-02-26","symbol":"NVZMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1740546000000,"reportTimeType":"","actualEps":null},{"date":"2024-09-09","symbol":"NVZMY","amount":0.29841,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-09","defaultRemindTime":1725888600000,"name":"NOVONESIS A S","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-18","payableDate":"2024-09-09","currency":"USD","dateTimestamp":1725854400000,"payDate":"2024-09-18"},{"market":"US","date":"2024-08-28","symbol":"NVZMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVZMY\",market:\"US\",,,undefined,":[{"executeDate":"2016-02-24","recordDate":"2016-02-26","paymentDate":"2016-03-15","value":0.327579,"currency":"USD"},{"executeDate":"2019-02-28","recordDate":"2019-03-01","paymentDate":"2019-03-19","value":0.504374,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":"2020-03-17","value":0.519405,"currency":"USD"},{"executeDate":"2021-03-12","recordDate":"2021-03-15","paymentDate":"2021-03-31","value":0.569924,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-04-05","value":0.845217,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVZMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0,"hold":0,"sell":0.3333,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":3,"updateTime":1759640400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVZMY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612428656","title":"Novonesis price target lowered to DKK 540 from DKK 560 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428656?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:51","pubTimestamp":1771437071,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Chetan Udeshi lowered the firm’s price target on Novonesis (NVZMY) to DKK 540 from DKK 560 and keeps an Overweight rating on the s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-lowered-to-dkk-540-from-dkk-560-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-lowered-to-dkk-540-from-dkk-560-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BDCRKT87.USD","LU2430703178.SGD","LU1917777945.USD","LU1668664300.SGD","LU2756315318.SGD","NVZMY","BK4516","SG9999002232.USD","LU1988902786.USD","LU0238689110.USD","BK4550","IE00BHPRN162.USD","LU2264538146.SGD","BK4566","LU1551013425.SGD","LU0882574139.USD","BK4533","LU2462157665.USD","IE00BWXC8680.SGD","LU0211327993.USD","LU0006306889.USD","LU2211815571.USD","LU1551013342.USD","LU0640476718.USD","IE00BJTD4N35.SGD","LU0976567544.SGD","LU0964807845.USD","BK4585","LU2023250330.USD","LU0265550359.USD","LU0265550946.USD","IE00BLSP4239.USD","LU1116320901.HKD","LU2746668461.USD","LU0820561909.HKD","LU0787776722.HKD","LU2237443622.USD","LU0868494708.USD","LU1119994496.HKD","LU1914381329.SGD","IE00BFXG1179.USD","LU2242649171.HKD","LU2237443895.HKD","LU0215105999.USD","LU2023250504.SGD","LU0070302665.USD","LU0203345920.USD","LU2106854487.HKD","LU1720051108.HKD","LU0345770308.USD"],"gpt_icon":0},{"id":"2587731620","title":"Novonesis price target raised to DKK 560 from DKK 512 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2587731620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587731620?lang=en_us&edition=fundamental","pubTime":"2025-11-29 01:25","pubTimestamp":1764350721,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Chetan Udeshi raised the firm’s price target on Novonesis (NVZMY) to DKK 560 from DKK 512 and keeps an Overweight rating on the sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-raised-to-dkk-560-from-dkk-512-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-raised-to-dkk-560-from-dkk-512-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1084165304.USD","LU1670627923.USD","LU2552382058.USD","IE0034235303.USD","BK4207","LU2462157665.USD","IE00BKVL7J92.USD","IE00BJTD4V19.USD","LU0345770308.USD","LU1064131342.USD","LU1670628061.USD","IE00BJLML261.HKD","LU2552382215.SGD","LU2552382132.HKD","LU1496350502.SGD","LU2456880835.USD","LU1720051108.HKD","LU0211326755.USD","LU0942090050.USD","LU0345770993.USD","LU2417539215.USD","LU0208291251.USD","LU1145028129.USD","LU0203345920.USD","BK4516","LU1244550494.USD","LU2023250330.USD","LU0689472784.USD","LU1894683348.USD","LU2237443549.SGD","LU2357305700.SGD","NVZMY","LU1244550221.USD","LU1720051017.SGD","LU0976567544.SGD","LU1162221912.USD","LU0149725797.USD","BK4534","LU0170899867.USD","LU2592432038.USD","IE00BYXW3230.USD","LU0310799852.SGD","LU2242649171.HKD","LU1974910355.USD","LU2237443895.HKD","LU0070302665.USD","LU1280957306.USD","LU1032466523.USD","IE00B1XK9C88.USD","LU0820561909.HKD"],"gpt_icon":0},{"id":"2586264068","title":"Novonesis price target lowered to DKK 560 from DKK 569 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2586264068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586264068?lang=en_us&edition=fundamental","pubTime":"2025-11-27 02:20","pubTimestamp":1764181231,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Thomas Wrigglesworth lowered the firm’s price target on Novonesis (NVZMY) to DKK 560 from DKK 569 and keeps an Overweight ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-lowered-to-dkk-560-from-dkk-569-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novonesis-price-target-lowered-to-dkk-560-from-dkk-569-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089283258.USD","LU1074936037.SGD","LU1720051108.HKD","LU1989772840.SGD","LU1363072403.SGD","LU2133065610.SGD","LU0528227936.USD","IE00BZ1G4Q59.USD","LU0557290698.USD","LU2089284900.SGD","LU2111349929.HKD","LU1244550221.USD","LU0106831901.USD","LU0795875169.SGD","LU0158827948.USD","LU0795875086.SGD","LU0971096721.USD","LU0234570918.USD","LU1791710582.SGD","LU0320765646.SGD","LU0098860793.USD","LU1244550494.USD","LU1989772923.USD","LU2271345857.HKD","BK4109","LU2357305700.SGD","BK4585","LU0158827781.USD","NVZMY","IE00BKVL7J92.USD","LU1791710400.SGD","LU0912757837.SGD","LU0225283273.USD","LU1720051017.SGD","BK4534","BK4581","BK4127","LU2023251221.USD","LU2028103732.USD","LU0314104364.USD","LU1244550577.SGD","LU0267386448.USD","LU0106261372.USD","LU1548497426.USD","LU1732799900.SGD","BK4588","LU1732800096.USD","LU0882574139.USD","BK4516","LU0006306889.USD"],"gpt_icon":0},{"id":"2581682980","title":"Press Release: Novonesis delivered 8% organic sales growth in the first nine months of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581682980","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581682980?lang=en_us&edition=fundamental","pubTime":"2025-11-06 18:12","pubTimestamp":1762423920,"startTime":"0","endTime":"0","summary":"Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.COPENHAGEN, Denmark -- November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%.- Strong broad-based organic sales growth of 8% , including the negative impact of exiting certain countries of 1 percentage point . Price contributed by 1 percentage point .- Food & Health at 9% organic sales growth  including the negative impact of exiting certain countries of 2 percentage points . Planetary Health at 8% organic sales growth .- Emerging Markets at 12% organic sales growth ; Developed Markets at 6% organic sales growth .2025 outlook: Organic sales growth is now expected between 7-8%  including an indication of mid-single-digit growth in Q4 following favorable timing in Q3. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% . The a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVZMY","BK4109"],"gpt_icon":0},{"id":"2565686613","title":"Novonesis and Novo Nordisk Collaborate to Improve Metabolic Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2565686613","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565686613?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:49","pubTimestamp":1757332140,"startTime":"0","endTime":"0","summary":"Danish biotech company Novonesis said it entered a research partnership with Novo Nordisk that will explore new solutions to improve metabolic health and potentially help prevent conditions such as obesity, diabetes and high blood pressure.The partnership will investigate how the microorganisms that naturally live in the gut, such as bacteria, fungi, and viruses, maintain metabolic health and how they could be used to monitor and predict health in individuals. It will also aim to explore solutions that preserve and optimize metabolic health.\"We are becoming increasingly aware of the role the gut plays in maintaining metabolic health and thereby minimizing the risk of developing obesity,\" Nadeem Sarwar, head of Novo Nordisk's transformational prevention unit said Monday.\"This new collaboration with Novo Nordisk enables us to deepen our understanding of the gut microbiome's role in maintaining metabolic health and to identify innovative products that support it,\" Henrik Joerck Nielsen, h","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVZMY","NVO","BK4109"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}